Abstract
Diabetic micro- and macroangiopathies are leading causes of acquired blindness, end-stage renal failure and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. Recent large landmark clinical studies have shown that intensive control of blood glucose or blood pressure (BP) reduces the risk for vascular complications in diabetes. However, the strict control of blood glucose or BP is often difficult to maintain, and current therapeutic options are far from satisfactory. Therefore, to develop novel therapeutic strategies that specifically target vascular complications in diabetes may be actually desired for most patients with diabetes. Pigment epithelium- derived factor (PEDF) is a glycoprotein that belongs to the superfamily of serine protease inhibitors with complex neurotrophic, neuroprotective, anti-angiogenic, anti-oxidative, and anti-inflammatory properties, any of which could potentially be exploited as a therapeutic option for the treatment of vascular complications in diabetes. This article summarizes the pathophysiological role of PEDF for vascular complication in diabetes and its potential therapeutic implication in this devastating disorder.
Keywords: Diabetic vascular complications, AGEs, oxidative stress, PEDF, RAGE
Current Drug Targets
Title: Pigment Epithelium-Derived Factor (PEDF): Its Potential Therapeutic Implication in Diabetic Vascular Complications
Volume: 9 Issue: 11
Author(s): Sho-ichi Yamagishi, Takanori Matsui, Kazuo Nakamura, So Ueda, Yoshihiro Noda and Tsutomu Imaizumi
Affiliation:
Keywords: Diabetic vascular complications, AGEs, oxidative stress, PEDF, RAGE
Abstract: Diabetic micro- and macroangiopathies are leading causes of acquired blindness, end-stage renal failure and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. Recent large landmark clinical studies have shown that intensive control of blood glucose or blood pressure (BP) reduces the risk for vascular complications in diabetes. However, the strict control of blood glucose or BP is often difficult to maintain, and current therapeutic options are far from satisfactory. Therefore, to develop novel therapeutic strategies that specifically target vascular complications in diabetes may be actually desired for most patients with diabetes. Pigment epithelium- derived factor (PEDF) is a glycoprotein that belongs to the superfamily of serine protease inhibitors with complex neurotrophic, neuroprotective, anti-angiogenic, anti-oxidative, and anti-inflammatory properties, any of which could potentially be exploited as a therapeutic option for the treatment of vascular complications in diabetes. This article summarizes the pathophysiological role of PEDF for vascular complication in diabetes and its potential therapeutic implication in this devastating disorder.
Export Options
About this article
Cite this article as:
Yamagishi Sho-ichi, Matsui Takanori, Nakamura Kazuo, Ueda So, Noda Yoshihiro and Imaizumi Tsutomu, Pigment Epithelium-Derived Factor (PEDF): Its Potential Therapeutic Implication in Diabetic Vascular Complications, Current Drug Targets 2008; 9 (11) . https://dx.doi.org/10.2174/138945008786786154
DOI https://dx.doi.org/10.2174/138945008786786154 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Therapeutic Strategies for Cardiorenal Protection in Patients with
Type 2 Diabetes and Chronic Kidney Disease
Current Vascular Pharmacology Risk Profiles in Type 2 Diabetes (Metabolic Syndrome): Integration of IL-10 Polymorphisms and Laboratory Parameters to Identify Vascular Damages Related Complications
Current Pharmaceutical Design Gas1 is a Pleiotropic Regulator of Cellular Functions: from Embryonic Development to Molecular Actions in Cancer Gene Therapy
Mini-Reviews in Medicinal Chemistry L-Carnosine Modulates Respiratory Burst and Reactive Oxygen Species Production in Neutrophil Biochemistry and Function: May Oral Dosage Form of Non-Hydrolized Dipeptide L-Carnosine Complement Anti-Infective Anti-Influenza Flu Treatment, Prevention and Self-Care as an Alternative to the Conventional Vaccination?
Current Clinical Pharmacology Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Current Pharmaceutical Design Preventing Atherosclerosis with Angiotensin-Converting Enzyme Inhibitors: Emphasis on Diabetic Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders Molecular Prevalence and Risk Factors of Gastroesophageal Reflux Disease in Hemodialysis Patients
Current Signal Transduction Therapy CCL2-CCR2 Signaling in Disease Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Perspectives on Medicinal Properties of Mangiferin
Mini-Reviews in Medicinal Chemistry Pediatric CKD and Cardivascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Mechanistic Insights Into Diabetes Mellitus and Oxidative Stress
Current Medicinal Chemistry Pharmacological and Clinical Applications of Natriuretic Peptides: Accepted Knowledges or Changing Views?
Current Pharmaceutical Analysis Vitamin D Receptor: A Novel Therapeutic Target for Kidney Diseases
Current Medicinal Chemistry Targeting Chromatin Remodeling to Prevent Cardiovascular Disease in Diabetes
Current Pharmaceutical Biotechnology Urotensin II: A Vascular Mediator in Health and Disease
Current Vascular Pharmacology Selenium Compounds Biotransformed by Mushrooms: Not Only Dietary Sources, But Also Toxicity Mediators
Current Nutrition & Food Science Editorial [ Receptor for Advanced Glycation Endproducts (RAGE): Coming Full Circle in Unraveling the Pathogenesis of Chronic Disease Guest Editor: Ann Marie Schmidt ]
Current Molecular Medicine Reactive Oxygen Species, Inflammation, and Lung Diseases
Current Pharmaceutical Design Mechanisms of Salt-Sensitive Hypertension
Current Hypertension Reviews Angiogenic Growth Factors in the Treatment of Peripheral Arterial Disease
Current Vascular Pharmacology